Overview

Neoadjuvant Phase 2 Study Comparing the Effects of AR Inhibition With/Without SRC or MEK Inhibition in Prostate Cancer

Status:
Active, not recruiting

Trial end date:
2023-09-30

Target enrollment:

Participant gender:

Summary

Prostate cancer is the most common cancer in men and the second leading cause of cancer death in men. The purpose of this research study is to compare prostate cancers treated with hormone therapy versus prostate cancers treated with hormone therapy plus drugs that directly target cancer cells.

Phase:

Phase 2

Details

Lead Sponsor:

Jonsson Comprehensive Cancer Center

Collaborators:

Astellas Pharma Inc
GlaxoSmithKline
Medivation, Inc.
Novartis
Prostate Cancer Foundation

Treatments:

Dasatinib
Trametinib